SCHEMBL4735874

SCHEMBL4735874

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCN4CCOCC4)c4noc(N)c34)cc2)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.82
FLT3 P36888 14/20 0.82
KIT P10721 10/20 0.82
FLT1 P17948 6/20 0.57
PDGFRB P09619 5/20 0.57
CSF1R P07333 4/20 0.57
TEK Q02763 1/20 0.57
HTR2A P28223 2/20 0.55
HTR2C P28335 2/20 0.55
RET P07949 3/20 0.55
AURKB Q96GD4 3/20 0.55
PDGFRA P16234 2/20 0.55
LTK P29376 2/20 0.55
CDK8 P49336 2/20 0.55
NTRK3 Q16288 2/20 0.55
NTRK2 Q16620 2/20 0.55
ALK Q9UM73 2/20 0.55
LCK P06239 3/20 0.55
IKBKE Q14164 2/20 0.55
MAP4K4 O95819 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739871 0.90 KDR (0.67) KDRFLT3KITFLT1PDGFRB
SCHEMBL423549 0.90 KDR (1.00) KDRFLT3KITFLT1PDGFRB
SCHEMBL1382868 0.88 KDR (0.74) KDRFLT3KITFLT1PDGFRB
SCHEMBL4786398 0.86 KDR (0.81) KDRFLT3KITFLT1PDGFRB
SCHEMBL421596 0.86 KDR (0.79) KDRFLT3KITFLT1PDGFRB
SCHEMBL3394108 0.83 KDR (0.78) KDRFLT3KITFLT1PDGFRB
SCHEMBL421556 0.82 KDR (0.78) KDRFLT3KITFLT1PDGFRB
SCHEMBL4740259 0.82 KDR (0.59) KDRFLT3KITFLT1PDGFRB
SCHEMBL4740470 0.81 KDR (0.76) KDRFLT3KITFLT1PDGFRB
SCHEMBL4740129 0.81 KDR (0.75) KDRFLT3KITFLT1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed